Cargando…
P16(INK4A) is required for cisplatin resistance in cervical carcinoma SiHa cells
Cervical cancer is the third most commonly diagnosed cancer worldwide and the fourth leading cause of cancer-related mortality in females worldwide, accounting for 10–15% of cancer-related mortalities. Cytological screening and DNA testing for high-risk human papillomavirus (HPV) types have markedly...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
D.A. Spandidos
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4315085/ https://www.ncbi.nlm.nih.gov/pubmed/25663864 http://dx.doi.org/10.3892/ol.2014.2814 |
_version_ | 1782355425616723968 |
---|---|
author | LI, YUERAN XIAO, SONGSHU DAN, LIU XUE, MIN |
author_facet | LI, YUERAN XIAO, SONGSHU DAN, LIU XUE, MIN |
author_sort | LI, YUERAN |
collection | PubMed |
description | Cervical cancer is the third most commonly diagnosed cancer worldwide and the fourth leading cause of cancer-related mortality in females worldwide, accounting for 10–15% of cancer-related mortalities. Cytological screening and DNA testing for high-risk human papillomavirus (HPV) types have markedly decreased the rates of cervical cancer in developed countries, however, for vulnerable populations without access to health care, cervical cancer remains a considerable problem. Chemotherapeutic agents such as cisplatin (DDP) are considered as first-line treatment for cervical carcinoma. Although initially patients often exhibit high responsiveness, the majority eventually develop DDP resistance. However, the mechanisms underlying this process remain unclear. Furthermore, patients with metastatic cancer and those exhibiting persistent or recurrent disease after platinum-based chemoradiotherapy have limited options and thus, non-platinum combination chemotherapy has been proposed as a strategy to circumvent platinum resistance, however, novel therapeutic strategies are required. In the present study, P16 expression was analyzed by quantitative-polymerase chain reaction and western blot analysis in SiHa and SiHa-DDP cells and the interaction between P16 and CDK4 was detected via co-immunoprecipitation. In addition, the proliferation and apoptosis rates of P16 knockdown SiHa-DDP cells were measured by MTT assay and Annexin V flow cytometry and the subsequent changes in cyclin D1 and pRb expression were analyzed by western blot analysis. In this study, a high level of P16(INK4A) expression and its enhanced interaction with cyclin-dependent kinase-4 in cervical carcinoma DDP-resistance cells (SiHa-DDP) was identified, which was associated with the inactivation of phosphorylated retinoblastoma protein (pRb). Knockdown of P16(INK4A) significantly induced cellular growth, when compared with the control cells, via the upregulation of pRb, and also promoted apoptosis following treatment with DDP. The results of this study indicated, for the first time, that P16(INK4A) is required for DDP resistance in cervical carcinoma SiHa cells and, thus, these results may lead to the development of novel strategies for the treatment of chemoresistant cervical carcinoma. |
format | Online Article Text |
id | pubmed-4315085 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | D.A. Spandidos |
record_format | MEDLINE/PubMed |
spelling | pubmed-43150852015-02-06 P16(INK4A) is required for cisplatin resistance in cervical carcinoma SiHa cells LI, YUERAN XIAO, SONGSHU DAN, LIU XUE, MIN Oncol Lett Articles Cervical cancer is the third most commonly diagnosed cancer worldwide and the fourth leading cause of cancer-related mortality in females worldwide, accounting for 10–15% of cancer-related mortalities. Cytological screening and DNA testing for high-risk human papillomavirus (HPV) types have markedly decreased the rates of cervical cancer in developed countries, however, for vulnerable populations without access to health care, cervical cancer remains a considerable problem. Chemotherapeutic agents such as cisplatin (DDP) are considered as first-line treatment for cervical carcinoma. Although initially patients often exhibit high responsiveness, the majority eventually develop DDP resistance. However, the mechanisms underlying this process remain unclear. Furthermore, patients with metastatic cancer and those exhibiting persistent or recurrent disease after platinum-based chemoradiotherapy have limited options and thus, non-platinum combination chemotherapy has been proposed as a strategy to circumvent platinum resistance, however, novel therapeutic strategies are required. In the present study, P16 expression was analyzed by quantitative-polymerase chain reaction and western blot analysis in SiHa and SiHa-DDP cells and the interaction between P16 and CDK4 was detected via co-immunoprecipitation. In addition, the proliferation and apoptosis rates of P16 knockdown SiHa-DDP cells were measured by MTT assay and Annexin V flow cytometry and the subsequent changes in cyclin D1 and pRb expression were analyzed by western blot analysis. In this study, a high level of P16(INK4A) expression and its enhanced interaction with cyclin-dependent kinase-4 in cervical carcinoma DDP-resistance cells (SiHa-DDP) was identified, which was associated with the inactivation of phosphorylated retinoblastoma protein (pRb). Knockdown of P16(INK4A) significantly induced cellular growth, when compared with the control cells, via the upregulation of pRb, and also promoted apoptosis following treatment with DDP. The results of this study indicated, for the first time, that P16(INK4A) is required for DDP resistance in cervical carcinoma SiHa cells and, thus, these results may lead to the development of novel strategies for the treatment of chemoresistant cervical carcinoma. D.A. Spandidos 2015-03 2014-12-19 /pmc/articles/PMC4315085/ /pubmed/25663864 http://dx.doi.org/10.3892/ol.2014.2814 Text en Copyright © 2015, Spandidos Publications http://creativecommons.org/licenses/by/3.0 This is an open-access article licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. The article may be redistributed, reproduced, and reused for non-commercial purposes, provided the original source is properly cited. |
spellingShingle | Articles LI, YUERAN XIAO, SONGSHU DAN, LIU XUE, MIN P16(INK4A) is required for cisplatin resistance in cervical carcinoma SiHa cells |
title | P16(INK4A) is required for cisplatin resistance in cervical carcinoma SiHa cells |
title_full | P16(INK4A) is required for cisplatin resistance in cervical carcinoma SiHa cells |
title_fullStr | P16(INK4A) is required for cisplatin resistance in cervical carcinoma SiHa cells |
title_full_unstemmed | P16(INK4A) is required for cisplatin resistance in cervical carcinoma SiHa cells |
title_short | P16(INK4A) is required for cisplatin resistance in cervical carcinoma SiHa cells |
title_sort | p16(ink4a) is required for cisplatin resistance in cervical carcinoma siha cells |
topic | Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4315085/ https://www.ncbi.nlm.nih.gov/pubmed/25663864 http://dx.doi.org/10.3892/ol.2014.2814 |
work_keys_str_mv | AT liyueran p16ink4aisrequiredforcisplatinresistanceincervicalcarcinomasihacells AT xiaosongshu p16ink4aisrequiredforcisplatinresistanceincervicalcarcinomasihacells AT danliu p16ink4aisrequiredforcisplatinresistanceincervicalcarcinomasihacells AT xuemin p16ink4aisrequiredforcisplatinresistanceincervicalcarcinomasihacells |